|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulen J and Jemal A: Global cancer statistics. 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Meloni-Ehrig AM: Renal cancer: Cytogenetic
and molecular genetic aspects. Am J Med Genet. 115:164–172. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Youssef YM, White NM, Grigull J, Krizova
A, Samy C, Mejia-Guerrero S, Evans A and Yousef GM: Accurate
molecular classification of kidney cancer subtypes using microRNA
signature. Eur Urol. 59:721–730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma W, Tao L, Wang X, Liu Q, Zhang W, Li Q,
He C, Xue D, Zhang J and Liu C: Sorafenib inhibits renal fibrosis
induced by unilateral ureteral obstruction via inhibition of
macrophage infiltration. Cell Physiol Biochem. 39:1837–1849. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tian X, Dai S, Sun J, Jiang S, Sui C, Meng
F, Li Y, Fu L, Jiang T, Wang Y, et al: Inhibition of MDM2
Re-sensitizes rapamycin resistant renal cancer cells via the
activation of p53. Cell Physiol Biochem. 39:2088–2098. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Krambeck AE, Dong H, Thompson RH, Kuntz
SM, Lohse CM, Leibovich BC, Blute ML, Sebo TJ, Cheville JC, Parker
AS, et al: Survivin and b7-h1 are collaborative predictors of
survival and represent potential therapeutic targets for patients
with renal cell carcinoma. Clin Cancer Res. 13:1749–1756. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
de Moor CH, Meijer H and Lissenden S:
Mechanisms of translational control by the 3′ UTR in development
and differentiation. Semin Cell Dev Biol. 16:49–58. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Barte DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fritz HK, Lindgren D, Ljungberg B, Axelson
H and Dahlbäck B: The miR21/10b ratio as a prognostic
marker in clear cell renal cell carcinoma. Eur J Cancer.
50:1758–1765. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kawakami K, Enokida H, Chiyomaru T,
Tatarano S, Yoshino H, Kagara I, Gotanda T, Tachiwada T, Nishiyama
K, Nohata N, et al: The functional significance of miR-1 and
miR-133a in renal cell carcinoma. Eur J Cancer. 48:827–836. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang H, Li M, Zhang R, Wang Y, Zang W, Ma
Y, Zhao G and Zhang G: Effect of miR-335 upregulation on the
apoptosis and invasion of lung cancer cell A549 and H1299. Tumour
Biol. 34:3101–3109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nishikawa R, Chiyomaru T, Enokida H,
Inoguchi S, Ishihara T, Matsushita R, Goto Y, Fukumoto I, Nakagawa
M and Seki N: Tumour-suppressive microRNA-29s directly
regulate LOXL2 expression and inhibit cancer cell migration
and invasion in renal cell carcinoma. FEBS Lett. 589:2136–2145.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu C, Liao Z, Cai M and Zhang G:
MicroRNA-320a downregulation mediates human liver cancer cell
proliferation through the Wnt/β-catenin signaling pathway. Oncol
Lett. 13:573–578. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lv Q, Hu JX, Li YJ, Xie N, Song DD, Zhao
W, Yan YF, Li BS, Wang PY and Xie SY: MiR-320a effectively
suppresses lung adenocarcinoma cell proliferation and metastasis by
regulating STAT3 signals. Cancer Biol Ther. 18:142–151. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Myatt SS and Lam EW: The emerging roles of
forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7:847–859.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xue YJ, Xiao RH, Long DZ, Zou XF, Wang XN,
Zhang GX, Yuan YH, Wu GQ, Yang J, Wu YT, et al: Overexpression of
FoxM1 is associated with tumor progression in patients with clear
cell renal cell carcinoma. J Transl Med. 10:2002012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Millour J, Constantinidou D, Stavropoulou
AV, Wilson MS, Myatt SS, Kwok JM, Sivanandan K, Coombes RC, Medema
RH, Hartman J, et al: FOXM1 is a transcriptional target of ERalpha
and has a critical role in breast cancer endocrine sensitivity and
resistance. Oncogene. 29:2983–2995. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Carr JR, Park HJ, Wang Z, Kiefer MM and
Raychaudhuri P: FoxM1 mediates resistance to herceptin and
paclitaxel. Cancer Res. 70:5054–5063. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mook OR, Frederiks WM and Van Noorden CJ:
The role of gelatinases in colorectal cancer progression and
metastasis. Biochim Biophys Acta. 1705:69–89. 2004.PubMed/NCBI
|
|
21
|
da Huang W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ge X, Cui H, Zhou Y, Yin D, Feng Y, Xin Q,
Xu X, Liu W, Liu S and Zhang Q: miR-320a modulates cell growth and
chemosensitivity via regulating ADAM10 in gastric cancer. Mol Med
Rep. 16:9664–9670. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang W, Zhao L, Wei X, Wang L, Liu S, Yang
Y, Wang F, Sun G, Zhang J, Ma Y, et al: MicroRNA-320a promotes 5-FU
resistance in human pancreatic cancer cells. Sci Rep. 6:276412016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lu Y, Wu D, Wang J, Li Y, Chai X and Kang
Q: miR-320a regulates cell proliferation and apoptosis in multiple
myeloma by targeting pre-B-cell leukemia transcription factor 3.
Biochem Biophys Res Commun. 473:1315–1320. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qi X, Li J, Zhou C, Lv C and Tian M:
MicroRNA-320a inhibits cell proliferation, migration and invasion
by targeting BMI-1 in nasopharyngeal carcinoma. FEBS Lett.
588:3732–3738. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Okato A, Goto Y, Kurozumi A, Kato M,
Kojima S, Matsushita R, Yonemori M, Miyamoto K, Ichikawa T and Seki
N: Direct regulation of LAMP1 by tumor-suppressive
microRNA-320a in prostate cancer. Int J Oncol. 49:111–122.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang B, Yang Z, Wang H, Cao Z, Zhao Y,
Gong C, Ma L, Wang X, Hu X and Chen S: MicroRNA-320a inhibits
proliferation and invasion of breast cancer cells by targeting
RAB11A. Am J Cancer Res. 5:2719–2729. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu J, Wang L, Yang H, Ding D, Zhang L,
Wang J, Chen Q, Zou Q, Jin Y and Liu X: Rab14 suppression mediated
by miR-320a inhibits cell proliferation, migration and invasion in
breast cancer. J Cancer. 7:2317–2326. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu J, Wang JG, Zhang L, Yang HP, Wang L,
Ding D, Chen Q, Yang WL, Ren KH, Zhou DM, et al: MicroRNA-320a
inhibits breast cancer metastasis by targeting metadherin.
Oncotarget. 7:38612–38625. 2016.PubMed/NCBI
|
|
31
|
Zhang N, Wei P, Gong A, Chiu WT, Lee HT,
Colman H, Huang H, Xue J, Liu M, Wang Y, et al: FoxM1 promotes
β-catenin nuclear localization and controls Wnt target-gene
expression and glioma tumorigenesis. Cancer Cell. 20:427–442. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Koo CY, Muir KW and Lam EW: FOXM1: From
cancer initiation to progression and treatment. Biochim Biophys
Acta. 1819:28–37. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhu GY, Shi BZ and Li Y: FoxM1 regulates
Sirt1 expression in glioma cells. Eur Rev Med Pharmacol Sci.
18:205–211. 2014.PubMed/NCBI
|
|
34
|
Kocarslan S, Guldur ME, Ekinci T, Ciftci H
and Ozardali HI: Comparison of clinicopathological parameters with
FoxM1 expression in renal cell carcinoma. J Cancer Res Ther.
10:1076–1081. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Raychaudhuri P and Park HJ: FoxM1: A
master regulator of tumor metastasis. Cancer Res. 71:4329–4333.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang Z, Zhang G and Kong C: FOXM1
participates in PLK1-regulated cell cycle progression in renal cell
cancer cells. Onco Lett. 11:2685–2691. 2016. View Article : Google Scholar
|
|
37
|
Luo X, Yao J, Nie P, Yang Z, Feng H, Chen
P, Shi X and Zou Z: FOXM1 promotes invasion and migration of
colorectal cancer cells partially dependent on HSPA5
transactivation. Oncotarget. 7:26480–26495. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Di Carlo A: Matrix metalloproteinase-2 and
−9 in the sera and in the urine of human, oncocytoma and renal cell
carcinoma. Oncol Rep. 28:1051–1056. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dumanskiy YV, Kudriashov AG, Vasilenko IV,
Kondratyuk RB, Gulkov YK and Cyrillichystiakov RS: Markers of
epithelial-mesenchymal transition in renal cell carcinoma. Exp
Oncol. 35:325–327. 2013.PubMed/NCBI
|
|
40
|
Kong FF, Zhu YL, Yuan HH, Wang JY, Zhao M,
Gong XD, Liu F, Zhang WY, Wang CR and Jiang B: FOXM1 regulated by
ERK pathway mediates TGF-β1-induced EMT in NSCLC. Oncol Res.
22:29–37. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Meng FD, Wei JC, Qu K, Wang ZX, Wu QF, Tai
MH, Liu HC, Zhang RY and Liu C: FoxM1 overexpression promotes
epithelial-mesenchymal transition and metastasis of hepatocellular
carcinoma. World J Gastroenterol. 21:196–213. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bao B, Wang Z, Ali S, Kong D, Banerjee S,
Ahmad A, Li Y, Azmi AS, Miele L and Sarkar FH: Over-expression of
FoxM1 leads to epithelial-mesenchymal transition and cancer stem
cell phenotype in pancreatic cancer cells. J Cell Biochem.
112:2296–2306. 2011. View Article : Google Scholar : PubMed/NCBI
|
